(Q37952621)

English

The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

urinary tract infection

1 reference

based on heuristic

inferred from title

author name string

Y-H Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

W-C Ko

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

P-R Hsueh

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

publication date

4 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1699-1704

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.1007/s10096-011-1457-x

0 references

Epidemiology of urinary tract infections: incidence, morbidity, and economic costs

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Relationship of catheter-associated urinary tract infection to mortality and length of stay in critically ill patients: a systematic review and meta-analysis of observational studies.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

European and Asian guidelines on management and prevention of catheter-associated urinary tract infections.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Which fluoroquinolones are suitable for the treatment of urinary tract infections?

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections?

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1457-X

21 January 2018

Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High rates of quinolone resistance among urinary tract infections in the ED.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The newer fluoroquinolones

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for antimicrobial therapy of urinary tract infections in Taiwan.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/22052606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10096-011-1457-X

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37952621&oldid=2088626053"